Palvella Therapeutics
PVLA
71 hedge funds and large institutions have $115M invested in Palvella Therapeutics in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 20 reducing their positions, and 19 closing their positions.
769% more call options, than puts
Call options by funds: $591K | Put options by funds: $68K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
20% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 20
0.02% more ownership
Funds ownership: 0.62% → 0.64% (+0.02%)
12% less funds holding
Funds holding: 81 → 71 (-10)
15% less capital invested
Capital invested by funds: $136M → $115M (-$20.9M)
53% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$11.3M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$2.47M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.13M |
| 4 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$1.68M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$1.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$2.93M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$2.88M |
| 3 |
Two Sigma Advisers
New York
|
-$2.2M |
| 4 |
Millennium Management
New York
|
-$1.69M |
| 5 |
Goldman Sachs
New York
|
-$945K |
PVLA Hedge Fund Activity: Q1 2022 in Review
71 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q1 2022, worth a combined $115M — down 15% from $136M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of PVLA and 9 opened new positions — a net loss of 10 holders — while 20 trimmed existing stakes and 24 added.
The largest buyer was Soleus Capital Management, adding an estimated $11.3M. The largest seller was Two Sigma Investments, cutting an estimated $2.93M.
- 71 institutional investors held Palvella Therapeutics (PVLA) as of Q1 2022, down from 81 in Q4 2021.
- Funds reported $115M of Palvella Therapeutics stock for Q1 2022, down 15% quarter-over-quarter.
- 9 funds opened new Palvella Therapeutics positions in Q1 2022 and 19 closed out, a net change of -10 holders.
- The largest Palvella Therapeutics buyer in Q1 2022 was Soleus Capital Management, an estimated $11.3M added.
- The largest Palvella Therapeutics seller in Q1 2022 was Two Sigma Investments, an estimated $2.93M sold.
Based on aggregated 13F filings for Q1 2022.